Franc Llorens

[Enric Vidal 🕊🏳️‍🌈 @vidal_enric]

Nova aportació de @FrancLlorens1 i el seu grup al diagnòstic de #CJD 👉🏻 #TREM2 un nou biomarcador en mostres de LCR de pacients amb malalties priòniques. 🧠 Una recerca finançada per @la_marato

Descarrega’t aquí el PDF de #ActaNeuropathologica 👉 https://t.co/ETeEY1fuQX

[Franc Llorens @FrancLlorens1]

Our new paper in @TheLancetNeuro
https://t.co/eEr2DzcEGE

[JM Virgili i Ortiga @Virgili7]

Llegiu-lo amb atenció i feu-ne cabal, si us plau.
https://t.co/lPMiVuiVb3
És un article excel·lent.

[Franc Llorens @FrancLlorens1]

@vidal_enric Per molts anys!

[Emilio del Río @emilio_delrio]

¿Qué diferencia hay entre los escépticos, los estoicos y los epicúreos? Filósofos bajo la lluvia lo explica de forma divertida (me han pasado esto por guasap y me ha parecido genial)

[Ziv Gan-Or @ZivGanOr]

I spent several hours today to thoroughly go over the available Aducanumab trial results.

I am now quite convinced that Aducanumab won't be efficient for Alzheimer's treatment.

One of the most revealing is this figure from the FDA presentation. 1/

[Dr. Guy Prochilo 🏳️‍🌈 @GuyProchilo]

An 'effect size' is a sample estimate of a population value with an associated level of uncertainty. When performing a power analysis based on published effect sizes, consider not only the point estimate but also the the width of the CI.

#phdchat

[Niklas Mattsson-Carlgren @NiklasMattsson4]

Plasma P-tau depends on both beta-amyloid and tau pathology in Alzheimer's disease. Early in the disease, plasma P-tau may be increased in response to beta-amyloid pathology. In later disease stages, plasma P-tau is associated with tau aggregation in the neocortex.

[Melcior Comes @MelciorComes]

Els polítics parlen com superherois. Els periodistes com polítics. Els narradors com poetes. I els poetes com bojos.

Vivim temps meravellosos.

[ShorterLab @ShorterLab]

Tau accumulation in astrocytes of the dentate gyrus induces neuronal dysfunction and memory deficits in Alzheimer’s disease: https://t.co/XhUTvGuZcN

[Pfizer Inc. @pfizer]

UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.

[Alzheimer's Drug Discovery Foundation @TheADDF]

#BreakingNews - The #FDA held an advisory committee today, which signaled in several votes that it does not believe the clinical study data for #Biogen #aducanumab supports the drug’s approval for patients with early stage #Alzheimers. @a_hfillit weighs in https://t.co/FAAIUvM9FJ

[Raquel Sánchez-Valle @sanchezvaller]

FDA advisory committee thumbs down on Biogen Alzheimer's candidate aducanumab https://t.co/IpXWb6CTZo

[Marc Suárez-Calvet 🧠🧪 🩺🌈 @M_SuarezCalvet]

https://t.co/XII64Mdqix

[Suvankar Pal @suvankarpal]

A comprehensive study by @NeilRJWatson1, collaborating with colleagues from the European CJD surveillance network, of 501 post mortem confirmed cases of sporadic #CJD. Confirms the utility of upgraded diagnostic criteria incorporating CSF RT-QuIC and MRI brain cortical ribboning

[Joan Anton Català Amigó @estelsiplanetes]

La fascinant refracció de la llum.
Aquí teniu un truc boníssim per a fer amb nens (i no tan nens!)
Si el voleu provar, es tracta que practiqueu abans la distància entre el paper, el got i els ulls. El líquid és, simplement, aigua.

[Prof. Feynman @ProfFeynman]

If you cannot explain something in simple terms, you don't understand it. 🧠

[Kariem Ezzat @Kariem_Ezzat]

Debate Follow-Up: Can Toxic Gain-of-Function (GOF) in Amyloid Pathologies Be Defended?
https://t.co/gqtNI7OO5S
@Sparks4PD

[Oded Rechavi @OdedRechavi]

Grant overhead